CE mark for Angeion's AngePass Lead System:
This article was originally published in Clinica
Executive Summary
Angeion has CE-marked its AngePass lead system which comprises both 4040 and 4080 models in the AngePass series. It is designed to lower energy thresholds required to convert critical cardiac arrhythmias to normal rhythm and intended for use with the company's Small Cap and Tuned biphasic waveform. The 4040 offers a tined passive fixation tip and is placed in the apex of the right ventricle. Alternatively, it could be augmented with the 4080 which is placed in the superior vena cava.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.